πŸ‡ΊπŸ‡Έ FDA
Patent

US 12043833

Targeted compositions

granted A61KA61K47/549A61K47/554

Quick answer

US patent 12043833 (Targeted compositions) held by ARBUTUS BIOPHARMA CORPORATION expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ARBUTUS BIOPHARMA CORPORATION
Grant date
Tue Jul 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K47/549, A61K47/554, A61P, A61P1/16